Myovant Sciences Ltd. Forms 3, 4 and 5: Warrants
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 8 rows, 8 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-04-17: Reporting owner Takeda Pharmaceuticals International AG; Form 4; Security Warrant to Purchase Common Shares; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-03-15: Reporting owner Takeda Pharmaceuticals International AG; Form 4; Security Warrant to Purchase Common Shares; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-02-15: Reporting owner Takeda Pharmaceuticals International AG; Form 4; Security Warrant to Purchase Common Shares; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-01-17: Reporting owner Takeda Pharmaceuticals International AG; Form 4; Security Warrant to Purchase Common Shares; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-04-17 | Takeda Pharmaceuticals International AG 10% Owner | 4 | Warrant to Purchase Common Shares Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,432 0 owned after | $0.00 | 2017-04-19 | |
| 2017-03-15 | Takeda Pharmaceuticals International AG 10% Owner | 4 | Warrant to Purchase Common Shares Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,091 0 owned after | $0.00 | 2017-03-24 | |
| 2017-02-15 | Takeda Pharmaceuticals International AG 10% Owner | 4 | Warrant to Purchase Common Shares Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,845 0 owned after | $0.00 | 2017-03-24 | |
| 2017-01-17 | Takeda Pharmaceuticals International AG 10% Owner | 4 | Warrant to Purchase Common Shares Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,727 0 owned after | $0.00 | 2017-03-13 | |
| 2016-12-15 | Takeda Pharmaceuticals International AG 10% Owner | 4 | Warrant to Purchase Common Shares Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −22,141 0 owned after | $0.00 | 2017-03-13 | |
| 2016-11-01 | Takeda Pharmaceuticals International AG 10% Owner | 4 | Warrant to Purchase Common Shares Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,977,269 0 owned after | $0.00 | 2016-11-03 | |
| 2016-10-27 holding as of filing | Takeda Pharmaceuticals International AG 10% Owner | 3/A | Warrant to Purchase Common Shares Derivative · Direct | Holding | no price filed | 2016-10-27 | ||
| 2016-10-26 holding as of filing | Takeda Pharmaceuticals International AG 10% Owner | 3 | Warrant to Purchase Common Shares Derivative · Direct | Holding | no price filed | 2016-10-26 |